Revvity, Inc. (ex Perkinelmer, Inc.) Strengths, Domain Expertise, and Key Differentiators
Revvity Signals Software is recognized for its enterprise software solutions designed to facilitate smarter decision-making among scientists, ultimately contributing to the development of more effective products and treatments. The aim is to empower scientists in achieving life-changing scientific breakthroughs.
PerkinElmer operates as a provider of products, services, and solutions within the diagnostics, life sciences, and applied markets. The company strategically markets its extensive range of products and services in over 190 countries worldwide.
Revvity, Inc. (ex Perkinelmer, Inc.) Recent Developments
In March 2022, Revvity Signals introduced V21 of its ChemDraw software, showcasing a noteworthy feature enabling the seamless import, animation, and sharing of 3D chemical structures directly within the Microsoft PowerPoint application with a single click. This significant enhancement, tailored for the millions of scientists globally utilizing the tool, facilitates the rapid creation of more intelligent research reports by chemists. The improved functionality fosters enhanced information sharing, collaboration, and real-time decision-making support. With the new ChemDraw V21 software, chemists can effortlessly insert a dynamic 3D representation of their molecule, complete with atom and bond color highlights, directly into Microsoft PowerPoint for viewing, rotation, and sharing. Additionally, researchers have the capability to save molecules as 3D printable objects, distinguishing ChemDraw V21 as the industry's sole chemical drawing application offering such intuitive features and eliminating the need for specialized software with challenging learning curves.
In October 2021, Revvity Signals introduced its Signals Research Suite, a comprehensive cloud-based solution deployed on Amazon Web Services. The suite, serving as a secure informatics platform, offers integrated end-to-end scientific data and workflow management tailored for pharmaceutical and industrial clientele. Engineered to facilitate informed and expedited decision-making regarding drug, compound, and formulation candidates, the solution amalgamates Revvity Signals' advanced informatics technologies spanning data access, processing, enhanced analytics, and collaboration. With the user-friendly and robust suite, multi-disciplinary R&D teams can consolidate crucial experiment and testing data, optimize workflow configurations, and proficiently manage essential scientific results without necessitating expertise in IT.
In November 2021, PerkinElmer, Inc., introduced the PKeye Workflow Monitor, a cloud-based platform that empowers laboratory personnel to remotely oversee and manage their PerkinElmer instruments and workflows in real-time.
In July 2020, PerkinElmer rolled out updates for Signals Notebook, incorporating several enhancements. Relevant CAS Numbers and density are now returned to Signals Notebook from ChemACX. The persistence of bookmarks and dashboards across terminals and browsers has been implemented, allowing chemists to seamlessly edit compounds in the Materials Library. Notably, bulk upload settings are now retained, and the consolidation of experiment and other object settings has been executed in the administrator console. Additionally, API endpoints related to Materials, Archive, and ChemDraw reactions have been either added or improved.
In June 2020, PerkinElmer released ChemDraw and ChemOffice version 19.1.1, designed to give chemists more time and provide innovative ways to enhance their research in a globally competitive environment. The upgraded ChemDraw software, a venerable 30-year-old product, offers enhanced features for the swift creation of publication-ready, chemically intelligent drawings. These drawings find utility in electronic laboratory notebooks, databases, publications, and facilitate chemical database queries, contributing to safer and more efficient research practices.
Revvity, Inc. (ex Perkinelmer, Inc.) Mergers and Acquisitions (M&A) Activities
In 2022, PerkinElmer underwent a split, leading to the divestiture of one segment encompassing its applied, food, and enterprise services businesses. This section was acquired by the private equity firm New Mountain Capital for $2.45 billion, resulting in its transition to private status while retaining the PerkinElmer name. Simultaneously, the remaining part, housing the life sciences and diagnostics businesses, remained publicly traded but necessitated a rebranding. In 2023, it was unveiled as Revvity, Inc. From Revvity's standpoint, the decision to establish a separate company aimed to enhance profit margins and unlock greater growth potential for its businesses. This strategic move also sought to provide increased financial flexibility for future endeavors. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.
In July 2021, PerkinElmer undertook its most significant acquisition to date, securing San Diego, Calif.-based BioLegend for $5.25 billion in cash and stock. Facilitated by bridge financing from Goldman Sachs, this marks PerkinElmer's fourth acquisition since the start of May. The recent additions include SIRION Biotech GmbH, a German viral vector-based technologies provider for cell and gene therapies (undisclosed amount); U.K.-based diagnostics firm Immunodiagnostic Systems Holdings PLC for $155 million in cash; and Lawrence-based Nexcelom Bioscience, specializing in automated cell-counting and imaging instruments, for $260 million.
Earlier in the year, PerkinElmer acquired Oxford Immunotec for $561 million and ES Industries for an undisclosed amount. The BioLegend acquisition, the largest in PerkinElmer's history, encompasses 700 U.S. employees, a comprehensive suite of antibodies and reagents for academic and biopharmaceutical clients, and the San Diego campus, slated to become PerkinElmer's "global Center of Excellence.
Revvity, Inc. (ex Perkinelmer, Inc.) Customers in ARTW Customer Database
Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying Revvity, Inc. (ex Perkinelmer, Inc.) applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of Revvity, Inc. (ex Perkinelmer, Inc.) and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified ChemDraw, ChemOffice, Signals ChemDraw, Signals Notebook, Signals Inventa, Signals VitroVivo customers.
Revvity, Inc. (ex Perkinelmer, Inc.) Overview
940 Winter Street
Waltham, MA, 2451, United States
1 781-663-6900
https://www.revvity.com/
Ownership: - NYSE: RVTY
Number of Employees: 11000
Functional Markets: Analytics and BI, Collaboration, Content Management, ERP Services and Operations, PLM,
Key Verticals: Healthcare, Life Sciences,
Revvity, Inc. (ex Perkinelmer, Inc.) Key Enterprise and Cloud Applications
ChemDraw, ChemOffice, Signals ChemDraw, Signals Notebook, Signals Inventa, Signals VitroVivo
Revvity, Inc. (ex Perkinelmer, Inc.) Revenues, $M:
| Type/Year | 2022 | 2023 | YoY Growth, % |
|---|---|---|---|
| Total Revenues, $M | Subscribe | Subscribe | Subscribe |
| Enterprise Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
| Cloud Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
* Enterprise Applications Revenues = License + Support & Maintenance + SaaS
** All revenue figures are estimates based on public records, Cloud and Non-Cloud business models in Apps Run The World's vendor database, and annual survey results including vendor feedback.
Revvity, Inc. (ex Perkinelmer, Inc.) Revenue Breakdown By Type, $M:
Revvity, Inc. (ex Perkinelmer, Inc.) Enterprise Applications Revenues By Functional Markets, $M:
Revvity, Inc. (ex Perkinelmer, Inc.) Enterprise Applications Revenues By Verticals, $M:
Revvity, Inc. (ex Perkinelmer, Inc.) Revenues By Region, $M
| Region | % of Total Revenues | 2023 Total Revenues, $M | 2023 Enterprise Applications Revenues, $M | 2023 Cloud Applications Revenues, $M |
|---|---|---|---|---|
| Americas | Subscribe | Subscribe | Subscribe | Subscribe |
| EMEA | Subscribe | Subscribe | Subscribe | Subscribe |
| APAC | Subscribe | Subscribe | Subscribe | Subscribe |
| Total | Subscribe | Subscribe | Subscribe | Subscribe |
Revvity, Inc. (ex Perkinelmer, Inc.) Direct vs Indirect sales
| Region | Direct Sales | Indirect Sales | Total |
|---|---|---|---|
| Type % | Subscribe | Subscribe | Subscribe |
| Revenues, $M | Subscribe | Subscribe | Subscribe |
Revvity, Inc. (ex Perkinelmer, Inc.) Customers - Breakdown by Geo, Size, Vertical and Product
List of Verified Revvity, Inc. (ex Perkinelmer, Inc.) Customers
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Customers: x
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Enterprise Applications Customers: x
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Cloud Customers: x
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Cloud Subscribers: x
PerkinElmer's customer base encompasses a diverse range of entities, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies.
Notable among the company's customers are organizations such as 4SC AG, Aarhus Universitet, Abraxis BioScience, Academia Sinica, Acadia Pharmaceuticals AB, Aceto Corporation, Achaogen, Inc., Achillion Pharmaceuticals, Acraf SpA, Acucela, Inc., Addex, Adesis Inc, Adherex Technologies Inc., Adolor Corporation, Advinus Therapeutics Pvt Ltd, AGES, Air Force Technical Applications Center, Air Products, Akzo Nobel NV, Alantos Pharmaceuticals, Albany College of Pharmacy, and Albany Molecular Research, Inc.
Revvity, Inc. (ex Perkinelmer, Inc.) Market Opportunities, M&A and Geo Expansions
In February 2022, TetraScience, the R&D Data Cloud company, initiated a collaborative effort with Revvity Signals business to enhance scientific decision-making for users of Revvity Signals Researchâ„¢ Suite, a prominent cloud-based electronic lab notebook and informatics platform. Millions of scientists globally, representing both leading and emerging research organizations, utilize Revvity Signal's informatics solutions to efficiently manage, process, analyze, and collaborate around crucial data, facilitating informed R&D and clinical decisions. Through this collaboration, TetraScience, via its Tetra R&D Data Cloud, will deliver Revvity Signals Research Suite customers vendor-agnostic, configurable, and productized instrument integrations. These integrations aim to improve data interoperability and reduce the time required to achieve scientific outcomes.
In April 2022, Scitara, a market-leading innovator in laboratory digital transformation, announced a collaboration with Revvity Signals to integrate the Revvity Signals Research Suiteâ„¢ informatics platform with laboratory instruments, applications, and resources through the Scitara Scientific Integration Platformâ„¢ SIPâ„¢. The Scitara SIP, operating within a cloud-native infrastructure, serves as a universal connectivity solution, enabling scientific laboratories using the Revvity Signals platform to fully embrace the benefits of digital transformation. This combined technological approach establishes a fully connected laboratory, emphasizing standard data integrity, data mobility, system flexibility, and user reconfigurability. This alignment with Revvity Signal's strategy reinforces its commitment to leveraging informatics solutions for driving digital transformation in the laboratory. Presently, over 2 million scientists in pharmaceutical, agrochemical, advanced materials, and food labs worldwide utilize Revvity Signal's cloud-based informatics solutions for research data capture, storage, analysis, collaboration, and data-driven R&D and clinical decisions.
In March 2021, Revvity Signals unveiled its expansion plans for its renowned Signals informatics platform, particularly focusing on bolstering capabilities within the biologics drug discovery sector. This expansion is the result of a collaboration with Insightful Science, a software company catering to the global life sciences community. Through this partnership, pharmaceutical and academic research teams can seamlessly integrate the Revvity Signals platform with leading solutions from Insightful Science’s Bioinformatics division, such as SnapGene and Geneious Prime software offerings. These tools aid molecular biologists in DNA construct design, molecular cloning, and various other molecular biology research tasks. The integration enables scientists to access and compare data from different experiments and instruments, fostering more intuitive collaboration. Additionally, scientists can replicate assays and experiments instantly, thereby accelerating time-to-result and facilitating more informed decision-making regarding drug and vaccine targets.
PerkinElmer's M&A strategy is yielding positive results, evident in its recent quarterly earnings report, where the company reported a remarkable revenue growth of over 51% compared to the same period last year. Buoyed by this success, PerkinElmer raised its full-year financial guidance by an additional $200 million. In 2019, the company successfully completed the acquisition of five businesses, involving a total consideration of $433.1 million.
Among these acquisitions, PerkinElmer added Ceiba Solutions, a sciences and laboratory IT software and services company, enhancing its OneSource services for streamlined laboratory operations. Additionally, the acquisition of CambridgeSoft bolstered PerkinElmer's life sciences software portfolio, contributing to increased efficiency in pharmaceutical, biotech, chemical, and scientific research sectors.
Revvity, Inc. (ex Perkinelmer, Inc.) Risks and Challenges
Operating in sectors marked by dynamic technological advancements, frequent product and service innovations, and evolving customer needs, PerkinElmer Informatics faces the inherent risk of intense competition. Rivals within these industries wield substantial financial resources, extensive intellectual property portfolios, vast experience in new product development, regulatory expertise, robust manufacturing capabilities, and established distribution channels. The company is exposed to potential challenges if the markets for its products witness a decline or fail to grow as anticipated. Factors such as economic downturns, uncertainties surrounding government or industrial funding proposals, or adverse alterations in government regulations could negatively affect PerkinElmer Informatics' business operations.
Revvity, Inc. (ex Perkinelmer, Inc.) Ecosystem, Partners, Resellers and SI
PerkinElmer businesses deploy their products and services primarily through dedicated sales forces. In regions without a direct sales and service presence, the company relies on distributors to facilitate product sales. Collaborative relationships extend to partner companies such as Fujitsu, Microsoft, Oracle, and Apple.
CambridgeSoft actively collaborates with other leading chemistry software firms to develop compatible interfaces, expanding the functionality of interconnected programs. Programs like Fujitsu's MOPAC, Gaussian, Inc.'s Gaussian program, and Schrödinger’s Jaguar seamlessly integrate with Chem3D. Exploring further integration possibilities, CambridgeSoft engages with partners like Accelrys to incorporate chemical components and applications. The company's growing ecosystem is additionally strengthened by a global network of resellers.
Revvity, Inc. (ex Perkinelmer, Inc.) Cloud Infrastructure Insights
Subscribe to read more about:
- Revvity, Inc. (ex Perkinelmer, Inc.) Public Cloud and Infrastructure (IaaS)
- Revvity, Inc. (ex Perkinelmer, Inc.) Platform (PaaS)
- Revvity, Inc. (ex Perkinelmer, Inc.) Application Delivery
- Revvity, Inc. (ex Perkinelmer, Inc.) Private Cloud and Data Centers
Research Methodology
Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.
Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).
For additional information on our methodologies, here's the link:
https://www.appsruntheworld.com/About Ushttps://www.appsruntheworld.com/taxonomy
https://www.appsruntheworld.com/FAQ
